Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 30, 2007 |
| Grant date | Dec 6, 2011 |
| Priority date | — |
| Expiry date | Jun 29, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70585
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.